LGALS3 and type 2 diabetes mellitus: Yu et al. [31] reported that the inhibition of Galectin-3 by TD139, an effective inhibitor of the galactoside binding pocket of Galectin-3, improved insulin resistance in HFD-induced mice, suggesting the potential of TD139 in the treatment of T2D.